Stay updated on Nivolumab with 5-azacytidine in Childhood AML Clinical Trial
Sign up to get notified when there's something new on the Nivolumab with 5-azacytidine in Childhood AML Clinical Trial page.

Latest updates to the Nivolumab with 5-azacytidine in Childhood AML Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2; this is a minor platform update with no changes to study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange Detected- Revision: v3.4.1 added; Revision: v3.4.0 removed.SummaryDifference0.1%

- Check33 days agoChange DetectedAdded UI text for glossary toggles (Show glossary, Hide glossary) and new policy/version labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0); removed the prior wording (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).SummaryDifference0.3%

- Check42 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

- Check63 days agoChange DetectedLocations were consolidated into a single 'Locations' section, replacing the previous separate state entries (California, Georgia, Maryland, New York, North Carolina, Ohio, Tennessee, Texas, Utah, Washington). The HHS Vulnerability Disclosure link was removed and the revision label updated to v3.3.3.SummaryDifference1%

- Check92 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; no study details or content appear to be changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab with 5-azacytidine in Childhood AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab with 5-azacytidine in Childhood AML Clinical Trial page.